To shed light on this complex subject, MPR interviewed Joshua D Brown, PharmD, PhD, Assistant Professor, Pharmaceutical Outcomes & Policy.
Familial hypercholesterolemia (FH), an inherited genetic disorder characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) levels, affects an estimated 620,000 Americans and is generally underdiagnosed and undertreated.
The FDA decision that 23andMe's Saliva Collection Kit and Personal Genome Service (PGS) should be classified as a medical device was highly controversial. Two experts weigh in on this complex issue.
Cardiac drug interactions make up almost 25% of all preventable adverse drug reactions.
When the Human Genome Project was completed in 2001, it was anticipated that by 2020 the pharmacogenomics approach for predicting drug responsiveness would become standard practice.